Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
Marksans Pharma Ltd

| Q2 FY26 Earnings Conference Call

BULLISH SENTIMENT

Report Source

⬤14th Nov 25

Summary : Marksans Pharma reported a strong Q2 FY26 recovery driven by US growth and operational efficiencies, with plans for significant capacity expansion and European market entry, despite ongoing UK pricing pressures.

Management Perspective positive : I am pleased to share that the Q2 FY'26 has been a strong quarter for the Company, reflecting a healthy recovery from a softer Q1. We are very optimistic on our growth strategy of doubling our revenue in the next 5 to 7 years. We are still very confident on the UK market, and we are still very bullish in our growth pattern.

Concall Report Analysis & Insights

Business Overview

  1. Q2 FY26 showed strong recovery with 16% sequential revenue growth.
  2. US business delivered robust performance; UK business stable with demand improvement.
  3. EBITDA and PAT grew 44% and 70% quarter-on-quarter.
  4. Unit 2 facility in Goa successfully completed US FDA inspection with zero observations.
  5. CARE rating upgraded to AA- with a stable outlook, reflecting sound financial position.

Future Growth Prospects

  1. Goal to double UK revenues over the next 5 to 7 years remains on track.
  2. Expanding into four European countries, with Germany starting organically in FY26.
  3. Planning to expand tablet capacity to 1.2-1.3 billion and soft gel capacity by 3x.
  4. Targeting 5,000 crores in revenue over the next five to seven years.
  5. New product launches in digestive health and pain management are gaining traction.

Management Insights

  1. Q2 FY26 was a strong quarter, reflecting healthy recovery from Q1.
  2. We are well-positioned to sustain growth for the remaining part of this year.
  3. Our product pipeline is strong and healthy, with many filings and expected approvals.
  4. We are very optimistic about doubling UK revenue in 5-7 years.
  5. We are aggressively pursuing smaller M&As across Europe in FY26.

Signs of Skepticism

  1. Long-term revenue target of 5,000 crores in 5-7 years seems ambitious.
  2. Organic expansion in Europe requires significant initial investment and time for returns.
  3. Management did not provide specific cost difference numbers with competitors like Perrigo.

Risk Factors

  1. Ongoing pricing pressure persists in the UK market.
  2. Tariff-related uncertainties, though stabilized, previously impacted business sentiment.
  3. Geopolitical issues could still make management pause on growth plans.
  4. Initial investments for organic expansion in new geographies are higher.
  5. Inflation and recessionary trends are concerns for global markets.

Good To Know

  1. US order book stands at $225-$230 million.
  2. Unit 2 facility is close to Rs. 500 crores in revenue based on recent statistics.
  3. Company remains debt-free with a cash balance of Rs. 666.5 crore as of September 30, 2025.
  4. Working capital cycle improved to 150 days, with further improvement expected.
  5. R&D spend in H1 FY26 was Rs. 26.2 crore, amounting to 2% of consolidated revenue.

Key Drivers

  1. New product launches in US.
  2. UK market approvals.
  3. European market expansion.
  4. Increased manufacturing capacity.

Key Analyst Discussions

Competitive Environment

  1. US private label OTC market is several billion dollars.
  2. Marksans is among the top four players in the US market.
  3. Competitors like Perrigo are pioneers, with 50 years of industry presence.
  4. Marksans leverages low-cost manufacturing base in India.

Market Trends & Consumer Behavior

  1. US tariff uncertainties have stabilized, improving business sentiment.
  2. Peak season for Western markets (US, Europe) is expected to boost Q3/Q4.
  3. Pricing pressure continues in the UK market.

Financial Highlights

  1. Q2 FY26 operating revenue was Rs. 720.4 crores, up 12.2% YoY.
  2. H1 FY26 operating revenue was Rs. 1,340.4 crores, up 8.8% YoY.
  3. Q2 EBITDA margin was 20.1%, with PAT at Rs. 99.1 crores.
  4. Expect FY26 full-year EBITDA margins to settle around 19-20%.
  5. Working capital days are expected to return to 120-130 days by Q1 FY27.

Product Composition

  1. New product launches in digestive health and pain management are driving traction.
  2. UK subsidiary Relonchem received three new marketing authorizations.
  3. Focus on high-margin, limited competition products in the UK.
  4. New approvals from Teva plant and other facilities will strengthen portfolio.

Strategic Considerations

  1. Planning to expand infrastructure in Goa with a CAPEX of around 100 crores in 2026.
  2. Exploring M&A opportunities in Europe, alongside organic expansion.
  3. Targeting four major European countries for market entry.
  4. Current capacity can support revenue up to 4,000 crores without major new investment.
  5. Diversifying into Canada by 2026 as a smaller market.